A GLP-1-free route to weight loss gains attention
TL;DR
A group of researchers behind GLP-1 obesity drugs propose an alternative: a high-dose molecule that activates GIP and glucagon receptors may achieve weight loss similar to GLP-1–targeting therapies, potentially with fewer side effects. The approach, funded by BlueWater Biosciences and described in Molecular Metabolism, is based on rodent and nonhuman primate data and has not yet been tested in humans, making findings uncertain and likely controversial for the field.
- Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target statnews.com
- New Weight Loss Research Questions Need for GLP-1 Drugs U.S. News & World Report
- Pharmalittle: We're reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more statnews.com
Want the full story? Read the original reporting
Read on statnews.com